Charles River Laboratories (CRL) Tops Q2 EPS by 28c; Offers Guidance
Tweet
Share
E-mail
Get Alerts CRL Hot Sheet
Price: $288.50 -1.65%
EPS Growth %: +21.8%
Financial Fact:
Net sales related to products: 132.87M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: +21.8%
Financial Fact:
Net sales related to products: 132.87M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Charles River Laboratories (NYSE: CRL) reported Q2 EPS of $3.02, $0.28 better than the analyst estimate of $2.74. Revenue for the quarter came in at $1 billion versus the consensus estimate of $976.13 million.
FY2026 Outlook-
EPS between $11.15 to $11.45 versus consensus $11.09.
For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Concurrent Technologies (CNC:LN) PT Raised to GBP3.20 at Berenberg
- Bernstein SocGen Group Reiterates Outperform Rating on Zydus Lifesciences (ZYDUSLIF:IN)
- Nomura/Instinet Upgrades MR DIY Group M Bhd (MRDIY:MK) to Buy
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
